JP2023547998A5 - - Google Patents

Info

Publication number
JP2023547998A5
JP2023547998A5 JP2023520040A JP2023520040A JP2023547998A5 JP 2023547998 A5 JP2023547998 A5 JP 2023547998A5 JP 2023520040 A JP2023520040 A JP 2023520040A JP 2023520040 A JP2023520040 A JP 2023520040A JP 2023547998 A5 JP2023547998 A5 JP 2023547998A5
Authority
JP
Japan
Prior art keywords
targeting component
component
psma
agent
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547998A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052269 external-priority patent/WO2022072292A1/en
Publication of JP2023547998A publication Critical patent/JP2023547998A/ja
Publication of JP2023547998A5 publication Critical patent/JP2023547998A5/ja
Pending legal-status Critical Current

Links

JP2023520040A 2020-10-01 2021-09-28 低分子リガンドの取り込み、内在化、及び／または保持を増加させるための方法及び組成物 Pending JP2023547998A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086163P 2020-10-01 2020-10-01
US63/086,163 2020-10-01
PCT/US2021/052269 WO2022072292A1 (en) 2020-10-01 2021-09-28 Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands

Publications (2)

Publication Number Publication Date
JP2023547998A JP2023547998A (ja) 2023-11-15
JP2023547998A5 true JP2023547998A5 (https=) 2024-09-26

Family

ID=80950775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520040A Pending JP2023547998A (ja) 2020-10-01 2021-09-28 低分子リガンドの取り込み、内在化、及び／または保持を増加させるための方法及び組成物

Country Status (7)

Country Link
US (1) US20230364271A1 (https=)
EP (1) EP4221763A4 (https=)
JP (1) JP2023547998A (https=)
AU (1) AU2021352915A1 (https=)
CA (1) CA3194592A1 (https=)
IL (1) IL301840A (https=)
WO (1) WO2022072292A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
EP3200823B1 (en) * 2014-10-02 2022-11-23 City of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
AU2018250609B2 (en) * 2017-04-11 2024-05-09 Adarga, Llc Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
MX2020010104A (es) * 2018-03-29 2020-11-06 Ambrx Inc Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.

Similar Documents

Publication Publication Date Title
JP2023547998A5 (https=)
JP2023547999A5 (https=)
Colcher et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72. 3) in patients with carcinoma
Bidkar et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy
Cives et al. Radionuclide therapy for neuroendocrine tumors
Lee et al. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma
Arnaldez et al. Targeting the insulin growth factor receptor 1
Li et al. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen
Mirallie et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer
JP2020518639A5 (https=)
Raoul et al. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides
Order et al. Radiolabeled antibodies: results and potential in cancer therapy
Niu et al. Current clinical application of lutetium‑177 in solid tumors
US20250312497A1 (en) Method of treating prostate cancer
CN120303009A (zh) 治疗前列腺癌的方法
Jiang et al. Applications of yttrium-90 (90Y) in hepatocellular carcinoma
De Bonis et al. Radioimmunotherapy for high-grade glioma
Beck et al. 213Bi‐radioimmunotherapy defeats early‐stage disseminated gastric cancer in nude mice
Liu et al. Autophagy inhibition improves the targeted radionuclide therapy efficacy of 131I-FAP-2286 in pancreatic cancer xenografts
Paprottka et al. Safety of radioembolization with 90Yttrium resin microspheres depending on coiling or no-coiling of aberrant/high-risk vessels
Heskamp et al. Alpha-versus beta-emitting radionuclides for pretargeted radioimmunotherapy of CEA-expressing human colon cancer xenografts
EP3302560A1 (en) Radio-imaging and radio-therapy of cancer using antibodies to haah
Du et al. Molecular radiotheragnostics in prostate cancer
JP5064608B2 (ja) アルファ粒子放出構成物およびその使用方法
Kunishio et al. Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression in pituitary adenoma.